Why OpenAi and Anthropic Are Racing to Become Biotech Companies

Alex Colville, PhD, is co-founder and General Partner of age1, the first longevity-focused venture fund, which he started with Laura Deming. He studied the biology of aging for his PhD in Genetics at Stanford and has managed more than $100 million in longevity investments. We discuss why Anthropic & OpenAi are suddenly buying biotech startups and racing to solve Ai drug discovery. And why tech billionaires + crypto founders are both allocating significant capital to this sector. Why the ChatGPT moment for aging is closer than you think. Alex explains why longevity is exploding now, the delay, replace, pause, reverse framework, stem cells, epigenetic reprogramming, reversible cryopreservation, NewLimit’s big bet, whether one cure exists, peptides, AI in biotech, zero-person biotechs, why AI labs are becoming biotechs, open source vs. secrecy, crypto founders’ longevity bets, the story behind age1, moonshots, helping dogs live longer, a Manhattan Project for aging, and the one bet he’d make today.